GlassScriptPhysician profile
Jamie L Willits
NPI 1821126913
$5,833.44
in general payments reported to CMS, 2019-2025
30 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.05 · 2022: $1,049 · 2023: $1,806 · 2024: $1,791 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,773.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.34 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $879.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $589.21 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $413.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $410.20 | 2023-2025 | Freestyle Libre, Proclaim |
| Pfizer INC. | $388.14 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $385.69 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $371.77 | 2022-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $292.95 | 2023-2025 | Veozah |
| Corium, LLC | $184.06 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $180.85 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.85 | 2022-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $66.30 | 2023-2025 | Trintellix |
| Medtronic, INC. | $66.11 | 2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $62.03 | 2023-2024 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.88 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $46.48 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $45.18 | 2022-2023 | Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $40.30 | 2022 | |
| Phathom Pharmaceuticals, INC. | $37.99 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $27.95 | 2021-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $26.00 | 2022 | |
| Inspire Medical Systems, INC. | $23.06 | 2025 | Inspire |
| Lundbeck LLC | $21.76 | 2024 | Rexulti |
| Si-Bone, INC. | $20.21 | 2025 | |
| Biogen, INC. | $20.08 | 2023 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $19.35 | 2023 | |
| Dexcom, INC. | $18.77 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Willits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.